Robert Driscoll
Stock Analyst at Wedbush
(3.08)
# 1,204
Out of 5,148 analysts
163
Total ratings
39.58%
Success rate
2.31%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Robert Driscoll
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EIKN Eikon Therapeutics | Initiates: Underperform | $7 | $14.88 | -52.96% | 1 | Feb 26, 2026 | |
| DAWN Day One Biopharmaceuticals | Maintains: Outperform | $29 → $30 | $10.37 | +189.30% | 7 | Feb 25, 2026 | |
| ARVN Arvinas | Maintains: Neutral | $9 → $11 | $13.39 | -17.85% | 10 | Feb 25, 2026 | |
| IDYA IDEAYA Biosciences | Maintains: Outperform | $49 → $52 | $33.04 | +57.38% | 10 | Feb 18, 2026 | |
| TYRA Tyra Biosciences | Maintains: Outperform | $37 → $53 | $32.52 | +62.98% | 10 | Feb 13, 2026 | |
| APRE Aprea Therapeutics | Maintains: Outperform | $11 → $7 | $0.89 | +690.87% | 4 | Feb 10, 2026 | |
| REPL Replimune Group | Maintains: Outperform | $18 → $19 | $7.16 | +165.36% | 8 | Feb 4, 2026 | |
| CGON CG Oncology | Initiates: Outperform | $70 | $57.76 | +21.19% | 1 | Dec 11, 2025 | |
| CGEM Cullinan Therapeutics | Maintains: Outperform | $25 → $34 | $15.99 | +112.63% | 5 | Dec 9, 2025 | |
| KURA Kura Oncology | Maintains: Outperform | $36 → $38 | $8.68 | +337.79% | 11 | Nov 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $77 → $80 | $101.62 | -21.28% | 8 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $38 | $8.35 | +355.09% | 2 | Oct 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $27 | $11.20 | +141.07% | 1 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $4 | $2.50 | +60.00% | 11 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $6 | $0.58 | +929.16% | 3 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $17 | $18.50 | -8.11% | 4 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $16 | $2.43 | +558.44% | 10 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $30 | $23.94 | +25.31% | 7 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $80 | $7.29 | +997.39% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $13 | $5.76 | +125.69% | 7 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $13 | $11.53 | +12.75% | 4 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $74 | $13.42 | +451.42% | 7 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $8 | $5.68 | +40.85% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $7 | $1.55 | +351.61% | 8 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $3 → $8 | $5.34 | +49.81% | 9 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $2 → $4 | $4.67 | -14.35% | 4 | May 19, 2020 |
Eikon Therapeutics
Feb 26, 2026
Initiates: Underperform
Price Target: $7
Current: $14.88
Upside: -52.96%
Day One Biopharmaceuticals
Feb 25, 2026
Maintains: Outperform
Price Target: $29 → $30
Current: $10.37
Upside: +189.30%
Arvinas
Feb 25, 2026
Maintains: Neutral
Price Target: $9 → $11
Current: $13.39
Upside: -17.85%
IDEAYA Biosciences
Feb 18, 2026
Maintains: Outperform
Price Target: $49 → $52
Current: $33.04
Upside: +57.38%
Tyra Biosciences
Feb 13, 2026
Maintains: Outperform
Price Target: $37 → $53
Current: $32.52
Upside: +62.98%
Aprea Therapeutics
Feb 10, 2026
Maintains: Outperform
Price Target: $11 → $7
Current: $0.89
Upside: +690.87%
Replimune Group
Feb 4, 2026
Maintains: Outperform
Price Target: $18 → $19
Current: $7.16
Upside: +165.36%
CG Oncology
Dec 11, 2025
Initiates: Outperform
Price Target: $70
Current: $57.76
Upside: +21.19%
Cullinan Therapeutics
Dec 9, 2025
Maintains: Outperform
Price Target: $25 → $34
Current: $15.99
Upside: +112.63%
Kura Oncology
Nov 14, 2025
Maintains: Outperform
Price Target: $36 → $38
Current: $8.68
Upside: +337.79%
Nov 6, 2025
Maintains: Outperform
Price Target: $77 → $80
Current: $101.62
Upside: -21.28%
Oct 20, 2025
Maintains: Outperform
Price Target: $31 → $38
Current: $8.35
Upside: +355.09%
Jul 14, 2025
Initiates: Outperform
Price Target: $27
Current: $11.20
Upside: +141.07%
May 15, 2025
Reiterates: Neutral
Price Target: $4
Current: $2.50
Upside: +60.00%
May 9, 2025
Maintains: Outperform
Price Target: $8 → $6
Current: $0.58
Upside: +929.16%
Mar 21, 2025
Maintains: Outperform
Price Target: $15 → $17
Current: $18.50
Upside: -8.11%
Oct 8, 2024
Reiterates: Outperform
Price Target: $16
Current: $2.43
Upside: +558.44%
Oct 3, 2024
Reiterates: Outperform
Price Target: $30
Current: $23.94
Upside: +25.31%
Sep 20, 2024
Reiterates: Outperform
Price Target: $80
Current: $7.29
Upside: +997.39%
Aug 9, 2024
Reiterates: Outperform
Price Target: $13
Current: $5.76
Upside: +125.69%
Aug 8, 2024
Maintains: Outperform
Price Target: $11 → $13
Current: $11.53
Upside: +12.75%
Aug 8, 2024
Reiterates: Outperform
Price Target: $74
Current: $13.42
Upside: +451.42%
Aug 7, 2024
Reiterates: Outperform
Price Target: $8
Current: $5.68
Upside: +40.85%
Jun 7, 2024
Reiterates: Outperform
Price Target: $7
Current: $1.55
Upside: +351.61%
May 9, 2024
Upgrades: Outperform
Price Target: $3 → $8
Current: $5.34
Upside: +49.81%
May 19, 2020
Upgrades: Outperform
Price Target: $2 → $4
Current: $4.67
Upside: -14.35%